ARTICLE | Finance
Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy
First investments focus on early-stage European cell and gene therapy
January 9, 2021 4:23 AM UTC
After a quiet first nine months, Paris-based VC Jeito ended 2020 with a trio of investments and a €50 million infusion by Sanofi. And while all three venture plays were in early-stage gene and cell therapy companies, Jeito founder and CEO Rafaèle Tordjman said her firm is not abandoning its founding strategy to invest from early to IPO while being modality agnostic.
“We are fine-tuning” with every pitch and investment, said Tordjman, who launched her firm with a €200 million ($223 million) fund at the J.P. Morgan Healthcare Conference last year after spending 15 years at Sofinnova Partners. ...